Battle lines drawn in adjuvant breast cancer
There’s no ASCO meeting without the Bean
After a long wait and much anticipation, the NATALEE late breaker results are finally in!
In this adjuvant breast cancer study involving Stage II/III disease, ribociclib was added to standard endocrine therapy (ET).
We have already seen the equivalent readouts from Pfizer and Lilly, with very different outcomes.
The Novartis trial followed same the positive trend as the Lilly study, but what about the subtleties and nuances involved?
Here we put the NATALEE trial through its paces and discuss the ins and outs relative to the niche…
To continue reading our latest highlights on oncology new product development including commentary and analysis, BSB subscribers can log-in or you can click to access the content.
This content is restricted to subscribers
